News articles about Caladrius Biosciences (NASDAQ:CLBS) have been trending positive on Saturday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Caladrius Biosciences earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.2486636648951 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

CLBS has been the topic of a number of research reports. Zacks Investment Research raised shares of Caladrius Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, May 15th. HC Wainwright set a $7.00 price target on shares of Caladrius Biosciences and gave the company a “buy” rating in a research note on Friday, May 19th. Finally, ValuEngine raised shares of Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 10th.

Caladrius Biosciences (NASDAQ:CLBS) opened at 3.97 on Friday. Caladrius Biosciences has a 52 week low of $2.65 and a 52 week high of $7.79. The company has a 50-day moving average of $4.11 and a 200-day moving average of $4.61.

Caladrius Biosciences (NASDAQ:CLBS) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.08. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 180.68%. On average, equities analysts predict that Caladrius Biosciences will post ($2.42) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/02/positive-media-coverage-somewhat-unlikely-to-affect-caladrius-biosciences-clbs-stock-price.html.

About Caladrius Biosciences

Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.

Insider Buying and Selling by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Receive News & Stock Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related stocks with our FREE daily email newsletter.